Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Empyrean Energy lit up the small-cap leaderboard this week, with shares rocketing 500 per cent after news of a game-changing ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...